Hitek Announces Entry into Share Purchase Agreement to Acquire an Advertising and Digital Marketing Company
XIAMEN, China, August 3, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company" or "Hitek"), an information technology consulting and solutions provider, today announced that, on August 3, 2026, it entered into a Share Purchase...
Nippon Paint China Debuts at ARCHIDEX 2026, Showcasing Industrial Innovations
KUALA LUMPUR, Malaysia, July 31, 2026 /PRNewswire/ -- Nippon Paint China made its debut at ARCHIDEX 2026, held from July 29 to August 1 at the Malaysia International Trade and Exhibition Centre in Kuala Lumpur. Invited to exhibit in the China...
Hitek Announces 1-for-25 Reverse Split
XIAMEN, China, July 1, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company"), an information technology consulting and solutions provider, announced today that it will effect a reverse split (the "Reverse Split") at a ratio of...
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for...
Tencent Rolls Out New AI Tools and Enterprise Solutions for Global Markets at Inaugural Tencent Cloud Day Hong Kong
Productivity agent WorkBuddy, creative agent Miora and Model-as-a-Service platform TokenHub launch globally to accelerate enterprise AI adoption HONG KONG, May 29, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global leading technology...
Hitek Announces 1-for-3 Reverse Split
XIAMEN, China, May 27, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company"), an information technology consulting and solutions provider, announced today that it will effect a reverse split (the "Reverse Split") at a ratio of...
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be...
Hitek Global Inc. Announces Fiscal Year 2025 Financial Results
XIAMEN, China, April 24, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company"), a China-based information technology consulting and solutions service provider, today announced its financial results for the fiscal year ended December...
Hitek Announces 50-for-1 Share Consolidation
XIAMEN, China, April 1, 2026 /PRNewswire/ -- HiTek Global Inc. (Nasdaq: HKIT) (the "Company"), an information technology consulting and solutions provider, announced today that it will effect a 50-for-1 share consolidation of its Class A ordinary...
Hitek Global Inc. Announces Pricing of $3 Million Registered Direct Offering
XIAMEN, China, March 28, 2026 /PRNewswire/ -- Hitek Global Inc. (NASDAQ: HKIT) ("Hitek Global" or the "Company"),a China-based information technology consulting and solutions service provider, today announced that it has entered into securities...